Emerging data suggest this peptide, a dual agonist targeting both GLP-1 and another hormone, could provide a significant step forward for body loss . Early patient tests have indicated substantial https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide